Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation

New York, New York (PRWEB) May 24, 2015

The federal court overseeing hundreds of testosterone treatment lawsuits (http://www.testosteronelawsuithub.com/) has scheduled its next monthly Case Management Conference to discuss the progress of the multidistrict litigation. According to court documents filed in the U.S. District Court, Northern District of Illinois, the Conference will be convened on June 2, 2015, at 1:30 p.m. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)

“Our Firm is representing clients who have filed testosterone lawsuits in this proceeding. We are looking forward to the June 2nd Conference, as it will likely include discussions regarding discovery, bellwether trial selection and other matters that could impact our clients’ cases,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free case reviews to men who may have been harmed by low testosterone therapy medications.

Testosterone Litigation

According to court documents, more than 1,400 testosterone lawsuits have been filed in the federal litigation underway in Illinois. The litigation was established in June 2014, several months after the U.S. Food & Drug Administration’s (FDA) announced that it was conducting a review of the cardiovascular risks potentially associated with the use of testosterone replacement therapy.* The results of that review were announced by the FDA on March 3, 2015, at which time the agency ordered the manufacturers of prescription testosterone treatments to modify their labels with information regarding a potential association with an increased risk of heart attack and stroke.

Court documents indicate that all of the claims pending in the federal litigation allege the manufacturers of testosterone replacement medications concealed their alleged association with heart attacks, strokes, blood clots and other life-threatening complications. Plaintiffs further assert that sales of low testosterone therapy products were driven by misleading marketing claims that positioned the drugs as safe and effective treatments for low libido, muscle loss, fatigue and other symptoms commonly associated with male aging, even though they have never been approved by the FDA for this purpose.

Men who allegedly experienced dangerous cardiovascular complications due to their use of low testosterone treatments may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

*http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm, FDA, January 31, 2014

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs’ firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Sandy A. Liebhard, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.testosteronelawsuithub.com/

https://plus.google.com/115936073311125306742?rel=author







DePuy ASR Lawsuit News: Federal Court Extends Deadline on Tolling Agreements for Non-Revision Plaintiffs, Bernstein Liebhard LLP Reports

New York, New York (PRWEB) December 28, 2014

The federal court overseeing thousands of DePuy ASR hip lawsuits (http://www.consumerinjurylawyers.com/DePuy/) has extended the deadline by which non-revision plaintiffs must decide to enter into a tolling agreement with Johnson & Johnson and its DePuy Orthopaedics unit, Bernstein Liebhard LLP reports. According to an Order posted December 24th on the website for the U.S. District Court, Northern District Ohio, such plaintiffs must now notify the Court by January 31, 2015 if they intend to continue with their case or voluntarily dismiss their lawsuit. Per an earlier court Order, plaintiffs who opt for voluntarily dismissal would enter into a tolling agreement with the defendants that would call for the refiling of their claim should they require revision of their ASR hip implant in the future.* (In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation – MDL 2197)

“We are representing numerous plaintiffs who have filed lawsuits in this proceeding. As non-revision plaintiffs are not eligible to participate in the settlement program announced last year, entering into a tolling agreement may be a viable option for these individuals,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices.

The Firm continues to offer free legal evaluations to individuals who allegedly experienced metallosis, chronic pain, disability, premature hip implant failure, and other serious complications allegedly related to devices included in the DePuy ASR recall.

DePuy ASR Litigation

According to court documents, the DePuy ASR hip recall was announced in August 2010, after data indicated that the metal-on-metal hips were failing at an unacceptably high rate within just five years of implantation. Since then, thousands of product liability claims have been filed in state and federal courts on behalf of individuals who allegedly suffered serious complications due to their ASR hips, most of which have been consolidated in a multidistrict litigation established in the Northern District of Ohio.

Last November, the Court announced the establishment of the DePuy ASR settlement program, which could ultimately resolve the majority of cases pending in state and federal courts. However, those eligible to participate in the program were limited to DePuy ASR recipients who underwent revision surgery to replace their implant due to a recall-related reason prior to August 31, 2013.

Individuals who allegedly suffered serious complications related to the DePuy ASR recall may be entitled to compensation for their injury-related damages. To learn more about the DePuy ASR litigation, please visit Bernstein Liebhard LLP’s website. For a free, no obligation case review, please call the Firm directly at 800-511-5092.

*ohnd.uscourts.gov/assets/CMO-24A.pdf, U.S. District Court, Northern District of Ohio, December 24, 2014

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.consumerinjurylawyers.com

https://plus.google.com/115936073311125306742?rel=author







Vaginal Mesh Lawsuit News: Boston Scientific Loses Bid for Summary Judgment on Negligence, Warning Claims in Federal Obtryx Case, Bernstein Liebhard LLP Reports

New York, New York (PRWEB) October 23, 2014

The federal judge overseeing thousands of vaginal mesh lawsuits (http://www.consumerinjurylawyers.com/transvaginal-mesh-recall-lawsuit.html) filed against Boston Scientific Corp. has denied the company’s Motion for Summary Judgment on negligence and warning claims put forth in one case involving the Obtryx Transobturator Mid-Urethral Sling System. The lawsuit, which is currently pending in the federal multidistrict litigation now underway in the U.S. District Court, Southern District of West Virginia, claims that the Obtryx device caused the plaintiff to suffer erosion, mesh contraction, infection, fistula, inflammation, scar tissue, organ perforation, and other serious vaginal mesh complications. According to an Order issued on October 17th, Judge Joseph R. Goodwin allowed her failure to warn, negligence and breach of warranty claims to go forward after finding that the lawsuit had established issues of fact as to the safety and effectiveness of the device. (Tyree, et al. v. Boston Scientific Corp., No. 2:12-8633)

According to court documents, this lawsuit is one of four Boston Scientific cases involving Obtryx mesh that have been consolidated for the proceeding’s first bellwether trial. That trial is scheduled to begin on November 3, 2014.

“Our Firm is closely monitoring the progress of vaginal mesh lawsuits filed against Boston Scientific Corp. and other companies, as we are representing hundreds of women in claims that put forth similar allegations,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free legal reviews to women who suffered mesh erosion, pain, scarring, infection and other serious transvaginal mesh complications, allegedly due to products marketed by a number of manufacturers.

Transvaginal Mesh Litigation

Court records indicate that Boston Scientific has been named a defendant in more than 14,000 vaginal mesh lawsuits that are currently pending in the Southern District of West Virginia. Bernstein Liebhard LLP partner, Jeffrey S. Grand, is serving as a member of the Plaintiffs’ Steering Committee for this proceeding. All the claims filed in this litigation similarly allege that pelvic mesh products marketed by Boston Scientific were defectively designed and manufactured, and caused women to suffer a wide variety of painful and debilitating transvaginal mesh complications. (In re: Boston Scientific Corp., Pelvic Repair Systems Products Liability Litigation – MDL No. 2326)

Court records indicate that more than 60,000 transvaginal mesh lawsuits are currently pending in several litigations underway in the Southern District of West Virginia. Mr. Grand isalso a member of the Plaintiffs’ Steering Committee for other federal proceedings, including those involving American Medical Systems, Inc. (MDL No. 2325), C.R. Bard, Inc. (MDL 2326) and Ethicon, Inc. (MDL No. 2327).

Mr. Grand was also appointed Co-Liaison Counsel in two multicounty litigations established for C.R. Bard and Ethicon mesh lawsuits in New Jersey’s Atlantic Superior Court. He was also a member of the trial team on the first Ethicon trial, which ended in March 2013 with an $ 11 million verdict for the Plaintiff. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10)

Women who were allegedly harmed by pelvic mesh products used to treat pelvic organ prolapse or stress urinary incontinence may be entitled to pursue a legal claim against the manufacturer of the device. To learn more about filing a vaginal mesh lawsuit, please visit Bernstein Liebhard LLP’s website or the firm’s Facebook page: https://www.facebook.com/meshlawsuit. To arrange for a free legal consultation, please call 800-511-5092

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info(at)consumerinjurylawyers(dot)com

http://www.consumerinjurylawyers.com

https://plus.google.com/115936073311125306742?rel=author







Find More Legal Press Releases

Xarelto Lawsuit News: New Study Says Treatment Strategies For Venous Thromboembolisms Have Bleeding Risks Reports Wright & Schulte LLC

Columbus, OH (PRWEB) October 12, 2014

Wright & Schulte LLC reports a recently released study found that most treatment options for blood clots in veins (venous thromboembolisms) are equally safe and effective yet major bleeding occurred in patients using the anticoagulants including Xarelto. The research, published in the September 17, 2014 issue of the Journal of the American Medical Association, examined eight different anticoagulant drugs, including unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), combined with vitamin K antagonists, which are also anticoagulants. Researchers from the University of Ottawa, Ontario, Canada, also included 45 randomized trials, which had a total number of 44,989 patients in their analyses. The study found nearly half of a percentage (0.49 percent) of patients had a major bleeding event during three months of treatment with Xarelto (rivaroxaban), and 0.29 percent had a major bleeding episode with Eliquis. The study’s authors concluded that, except for the UFH-vitamin K antagonist combination, all other treatment strategies had bleeding risks similar to the LMWH-vitamin K antagonist combination. As studies continue on the effectiveness of anticoagulants such as Xarelto, court records indicate that Xarelto lawsuits allege that major bleeding events are side-effects of taking the Xarelto blood thinner and there is no antidote to reverse the uncontrolled bleeding, one of which was filed the U.S. District Court, Eastern District of New York (Case No. 1:14-cv-04841-FB-VMS)

[media.jamanetwork.com/news-item/study-compares-effectiveness-of-treatments-for-blood-clots/, September 16, 2014.]

The attorneys at Wright & Schulte continue to investigate claims of uncontrolled bleeding due to Xarelto and offer free legal claims to men and women who believe they have experienced bleeding side-effects from Xarelto and other anticoagulant drugs by calling 1-800-399-0795 or by visiting http://www.yourlegalhelp.com for information on this and other medication news.

Xarelto is a new-generation oral blood thinner first approved by the U.S. Food & Drug Administration (FDA) in July 2011 to reduce deep vein thrombosis and pulmonary embolism in patients who had knee or hip replacement surgery. In November 2011, FDA expanded approval for Xarelto to treat deep being thrombosis. In November 2012, Xarelto was approved to treat and prevent recurrence of deep vein thrombosis and pulmonary embolism and to reduce the risk of the conditions recurring following initial treatment. Unlike warfarin (Coumadin, Jantoven), a blood thinner approved by the FDA in 1954, Xarelto does not have a specific reversal agent should significant bleeding occur. Vitamin K is used as the antidote for patients taking warfarin.

[fda.gov/newsevents/newsroom/pressannouncements/ucm326654.htm, November 2, 2012]

[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]

Court documents indicate that Xarelto lawsuits are being filed in courts throughout the United States, including a wrongful death lawsuit filed on August 14, 2014, in the U.S. District Court, Eastern District of New York on behalf of a 92-year-old Tennessee man. (Case No. 1:14-cv-04841-FB-VMS) According to the Xarelto complaint, the Tennessee man first began using the blood thinner medication from May 2013 and continued to use until August 2013. The Xarelto lawsuit alleges that due to using Xarelto, the man suffered life-threatening bleeding on August 25, 2013, and sustained severe and permanent personal injuries, pain, suffering and emotional distress. The man died on December 6, 2013. The Xarelto complaint purports that defendants Jannssen Pharmaceuticals and Bayer failed to warn emergency room doctors and other medical professionals as well as disclose to patients that there is no effective agent to reverse the anticoagulation effects of Xarelto, and therefore there is no effective means to treat and stabilize patients who experience uncontrolled bleeding while taking Xarelto.

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free low testosterone lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:

Wright & Schulte LLC

812 East National Road

Vandalia, Ohio 45377

1-800-399-0795

http://www.yourlegalhelp.com

Like us on Facebook

Follow us on Twitter

Join us on Google+







Find More Law Press Releases